1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E6B123FE1E7DB67F85256EB00058B750
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/improve-pharmaceutical-clinical-trials-efficiency?opendocument
18
19opendocument
2018.206.48.142
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Clinical Operations Patient Recruitment and Retention for Clinical trials

Key Factors in Improving Pharmaceutical Clinical Trials

DB Image

ID: 4670


Features:


Pages/Slides: 9


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Study Overview

As competition for clinical investigators and patients within the pharmaceutical industry continues to intensify, the need for pharmaceutical companies to improve the clinical trial process becomes urgent. Pharmaceutical companies can use the information in this document to shorten their own clincial development process. Shortening this process saves both time and the cost of conducting the studies and delivers a higher overall return on investment. This nine-page document details the way top pharmaceutical companies improve clinical development efficiency through the use of an effective communication plan.

Key Topics

  • development of strategy for targeting patients and sites
  • motivations of investigators to participate in trial
  • communication efficiency between pharmaceutical companies and study sites
  • acceleration of patient recruitment
  • retention and motivation of patients


Sample Best Practices
  • Develop a clear targeting strategy to focus recruitment efforts of investigators and study sites.
    *Interviewed executives note that without clear and appropriate targets, dollars spent on communications programs, no matter how well designed and executed, will not yield positive returns.
  • Employ timely and frequent communications to inform and motivate study sites.
    *To avert communication problems, some interviewed sites prefer communicating directly with pharmaceutical companies. This direct contact can provide quick, clear and authoritative answers to questions.
  • Provide customized communication materials and benefits to retain and motivate patients.
    *Some companies offer take-home educational materials that openly discuss the study and its possible effects and outcomes. This helps retain patients who may drop out of a study because their partners or other family members feel uneasy about their loved ones taking a new drug with perceived risks.


Methodology
This research originated from a Best Practices, LLC consulting project.

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Research; Professional Services


Companies Profiled:
AstraZeneca; Sanofi-aventis; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; Pfizer; Roche; Trimeris; aaiPharma; America's Doctor; BBK Healthcare; Covance; Health Decisions; PPD

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.